ClinicalTrials.gg
CompletedNCT03289702Updated Dec 7, 2021

CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase3)

A Phase 3 interventional study of CORETOX® and BOTOX® in Muscle Spasticity, sponsored by Medy-Tox. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2021-12-07.

Sponsored by Medy-Tox · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 19 studies in Muscle Spasticity with a site in Korea, Republic of — 1 open to participants now, 1 under way, none of them phase 3. Muscle Spasticity · Korea, Republic of.

Enrollment
7th of 17
220 · median 212
Started
2017
with 1 other
Phase 3
9 of 19
none open now
Registered
15th of 19
by date
Lead sponsor
4 of 19
Medy-Tox

Among the 19 studies in Muscle Spasticity with a site in Korea, Republic of, this one is the 7th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2017, is one of 9 in phase 3, and was the 15th registered.

Muscle Spasticity

624 studies on the registry are indexed under Muscle Spasticity; 130 are open to participants now.

Browse Muscle Spasticity studies →

Open to participants now

1 of the 19 studies in Muscle Spasticity with a site in Korea, Republic of is open now. Recruiting first, the newest first:

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 88 Muscle Spasticity studies recruiting now, 29 (33%) set no upper age limit and 47 (53%) stop at 75 or younger; 34 take children under 18; 11 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Muscle Spasticity with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of CORETOX® in the treatment of post-stroke upper limb spasticity

03

Conditions studied

  • Muscle Spasticity

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients ≥ 19 years
  • ≥ 6 months since the last stroke
  • ≥ 2 points in the focal spasticity of wrist flexor and ≥ 1 point at least one of elbow flexor and finger flexor as measured on MAS(0 to 4)
  • has been obtained

Exclusion criteria

Exclusion Criteria:

  • Neuromuscular disorders such as Lambert-Eaton syndrome, myasthenia gravis, or amyotrophic lateral sclerosis
  • History(within 4 months of screening visit) or planned(during study period) treatment with phenol or alcohol injection or surgery in the target limb
  • History(within 4 months of screening visit) or planned(during study period) treatment with tendon lengthening in the target limb
  • Fixed joint/muscle contracture
  • Severe atrophy
  • Concurrent treatment with an intrathecal baclofen
  • Patients who have bleeding tendency or taking anti-coagulant
  • Dysphagia and Breathing Difficulties
  • History(within 4 months of screening visit) Planned(during study period) treatment with Botulinum Toxin
  • Known allergy or sensitivity to study medication or its components
  • Concurrent or planed Muscle relaxants and/or benzodiazepine medication If patient has taken these medication stable from one month before screening and no treatment changes are not planned during the study, participation is allowed.
  • Current Physical, occupational, Splinting therapy These therapy regimens will be permitted if they have been stable in the one month before screening; no treatment and no changes are planned during the study.
  • Patient who are participating in other clinical trials at the screening
  • Females who are pregnant, breastfeeding, or planning a pregnancy during the study period, or female of , not using a reliable means of .
  • Patients who are not eligible for this study at the discretion of the investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
220 participants (actual)

Study arms

  • Experimental
    CORETOX®

    Drug: CORETOX®

  • Active comparator
    BOTOX®

    Drug: BOTOX®

Interventions

  • Upper limb will be injected and evaluated in the study. Maximum injection dose is 360U.

  • Upper limb will be injected and evaluated in the study. Maximum injection dose is 360U.

06

What researchers measure

Primary outcomes

  1. MAS(Modified Ashworth Scale)of wrist flexor

    Change from baseline at week 4 for wrist flexor muscle tone as measured on the MAS(Modified Ashworth Scale)

    Time frame: 4 weeks

Secondary outcomes

  1. MAS(modified Ashworth Score)of elbow and finger flexor

    Change from baseline at week 4 for elbow flexor and finger flexor muscle tone as measured on MAS

    Time frame: 4 weeks after injection

  2. MAS(modified Ashworth Score)of wrist, elbow and finger flexor

    Change from baseline at week 8, 12 for wrist flexor, elbow flexor and finger flexor muscle tone as measured on MAS

    Time frame: 8, 12 weeks after injection

  3. Percentage of treatment responder at week 4, 8, 12 after injection

    A treatment response is defined as 1-point improvement on the MAS of injection site

    Time frame: 4, 8, 12 weeks after injection

07

Study locations

1 site
  • Asan Medical Center
    Seoul, Korea, Republic of
08

References and documents

Publications

  • Lee J, Chun MH, Ko YJ, Lee SU, Kim DY, Paik NJ, Kwon BS, Park YG. Efficacy and Safety of MT10107 (Coretox) in Poststroke Upper Limb Spasticity Treatment: A Randomized, Double-Blind, Active Drug-Controlled, Multicenter, Phase III Clinical Trial. Arch Phys Med Rehabil. 2020 Sep;101(9):1485-1496. doi: 10.1016/j.apmr.2020.03.025. Epub 2020 Jun 1. PubMed 32497599 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Jun 2018, 7 months.

Of 16 phase 3 interventional studies under Muscle Spasticity, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 57. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2017
First posted
Sep 21, 2017
StartActual
Nov 13, 2017
Primary completionActual
Jun 30, 2018
CompletionActual
Nov 9, 2018
Last update
Dec 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03289702
Lead sponsor
Medy-Tox
Responsible party
Sponsor
First posted
Sep 21, 2017
Start date
Nov 13, 2017
Primary completion
Jun 30, 2018
Completion
Nov 9, 2018
Last update
Dec 7, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Coretox

Start the discussion